2024
The impact of MELD exception points for hydrothorax on posttransplant mortality: a propensity score-matched analysis
Fathma S, Boateng S, Amatya A, Ameyaw P, Banini B. The impact of MELD exception points for hydrothorax on posttransplant mortality: a propensity score-matched analysis. European Journal Of Gastroenterology & Hepatology 2024, 36: 1016-1021. PMID: 38829948, PMCID: PMC11230850, DOI: 10.1097/meg.0000000000002792.Peer-Reviewed Original ResearchUnited Network for Organ SharingEnd-stage liver diseaseHepatic hydrothoraxMELD exception pointsScore matching analysisMELD exceptionsPosttransplant mortalityLiver transplantationComplications of end-stage liver diseaseLiver diseaseChild-Pugh grade CUnited Network for Organ Sharing DatabasMultivariate logistic regressionDecompensated cirrhosisSerum creatinineNo significant differenceTransplant databaseMELD scoreClinical decision-makingNational transplant databaseCombined cohortLaboratory valuesGrade CHydrothoraxPosttransplant death
2023
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong G, Dashti F, Banini B. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Annals Of The New York Academy Of Sciences 2023, 1526: 16-29. PMID: 37400359, PMCID: PMC10524684, DOI: 10.1111/nyas.15012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseNonalcoholic fatty liverLiver diseaseRisk factorsCommon chronic liver diseaseEnd-stage liver diseaseNatural historyNAFLD risk factorsChronic liver diseaseFatty liver diseaseCurrent management strategiesClinicopathologic spectrumLiver transplantationNonalcoholic steatohepatitisProgressive fibrosisFatty liverHepatocellular cancerLeading indicationDiseaseUnited StatesManagement strategiesCirrhosisSteatohepatitisTransplantationFibrosis
2017
Current and future pharmacologic treatment of nonalcoholic steatohepatitis
Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current Opinion In Gastroenterology 2017, 33: 134-141. PMID: 28346237, PMCID: PMC5491795, DOI: 10.1097/mog.0000000000000356.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseEnd-stage liver diseaseNonalcoholic steatohepatitisLiver diseaseTrend of NAFLDChemokine receptor type 2Future pharmacologic treatmentsCornerstone of therapyStage liver diseaseFatty liver diseasePeroxisome proliferator activator receptorProgression of fibrosisAnti-inflammatory agentsDietary caloric restrictionGlucagon-like peptide 1 pathwayReceptor type 2Liver histologyMetabolic endotoxemiaPharmacologic treatmentTherapeutic optionsHepatocellular cancerAntifibrotic agentsIntestinal microbiomeAggressive formPharmacologic target
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply